- Japan
- Market Indicator
- Price Momentum Indicators
- Richard Russell
- Silver
- Speed Resistance Lines
- U.S. Dividend Watch List
Category Archives: biib
Biogen Price Momentum Indicator
Below is the Price Momentum Indicator for Biogen Inc. (BIIB).
Biogen Management Should Provide Proper Sell Signal
Source:
Sundry Items
-
Biogen Idec (BIIB) and Teva Pharmaceutical (TEVA) are doing a dance as both are members of the Nasdaq 100 index. As one stock is at a new high the other is reaching a new low. The two-step that is being done by the stocks is quite amazing. Back in October 30, 2009, we pointed out that the concentration of biotech stocks at a new low meant that they were possible takeover candidates. From that list in 2009, GENZ and CEPH were actually tendered buyout offers. 3 of the remaining 5 biotechs have had gains of 40% or more since then. The remaining two stocks, Amgen and Gilead Sciences, are essentially at break even. BIIB has been the leader in terms of price appreciation with a gain of over 100% since October 30, 2009. At that time TEVA was near a new 52-week high. However, BIIB’s recent success is actually impacting the performance of TEVA since both companies are involved in the development in MS drugs. TEVA is now on our new low list for the Nasdaq 100 and should be consider as a top acquisition candidate for your portfolio. Anyone who bought BIIB based on our watch list from October 2009 should now consider securing a large portion of the gains and possibly funding the purchase of TEVA with the proceeds.
-
Our September 5, 2009 article titled “Silver Should be the Focus” recommended that anyone interested in investing in gold should instead put there investment funds towards silver. The chart below reflecting the silver (SLV) and the gold (GLD) ETF demonstrates the accuracy of our recommendation and highlights what we believe is likely to come. Those interested in determining an entry point should reference our latest article on April 14, 2011 highlighting the downside targets for precious metal stocks based on the Philadelphia Gold and Silver Stock Index (XAU).
-
The results are in and our article titled “A Comparison Between Dividend Strategies” has demonstrated, so far, that the New Low approach has returned 19.52% while the list of stocks we compared ourselves to has returned only 1.39%. We believe that, although the two list have similar companies, the quality and timing has made the difference in performance. As a note, we only made the comparison because the author of the other list indicated that it was for the purpose of trading. In our view, stocks that can be considered for trading are worth comparing since we only aim for 1-year performance.
Genzyme Corp: Value is Finally Being Recognized
Nasdaq 100 Watch List
| Name (SYMBOL) | Price | P/E | EPS | Yield | P/B | Pct from Yr Low |
| Activision Blizzard, Inc (ATVI) | $10.69 | 45.49 | 0.24 | 1.40% | 1.25 | 7.65% |
| Amgen Inc. (AMGN) | $54.69 | 11.61 | 4.71 | 0.00% | 2.42 | 15.14% |
| Apollo Group, Inc. (APOL) | $52.78 | 13.2 | 4 | 0.00% | 6.18 | 1.11% |
| Biogen Idec Inc (BIIB) | $50.13 | 15.18 | 3.3 | 0.00% | 2.32 | 20.07% |
| Cephalon, Inc. (CEPH) | $60.69 | 12.1 | 5.01 | 0.00% | 1.98 | 15.49% |
| Electronic Arts Inc. (ERTS) | $17.42 | 0 | -2.31 | 0.00% | 2.28 | 10.96% |
| Genzyme Corporation (GENZ) | $50.43 | 122.4 | 0.41 | 0.00% | 1.83 | 7.09% |
| Gilead Sciences, Inc. (GILD) | $37.78 | 12.12 | 3.12 | 0.00% | 4.74 | 0.61% |
| Logitech (LOGI) | $14.74 | 40.72 | 0.36 | 0.00% | 2.69 | 14.89% |
| QUALCOMM (QCOM) | $37.30 | 19.89 | 1.88 | 2.00% | 3 | 5.88% |
| Ryanair Holdings plc (RYAAY) | $24.72 | 0 | 0 | 0.00% | 0 | 4.39% |
| Sigma-Aldrich (SIAL) | $54.23 | 18.5 | 2.93 | 1.20% | 4.01 | 21.00% |
| Staples, Inc. (SPLS) | $22.12 | 21.62 | 1.02 | 1.60% | 2.39 | 18.16% |
| Stericycle, Inc. (SRCL) | $56.70 | 26.83 | 2.11 | 0.00% | 5.49 | 21.00% |
| Symantec Corporation (SYMC) | $16.12 | 18.49 | 0.87 | 0.00% | 2.89 | 15.39% |
| Yahoo! Inc. (YHOO) | $16.39 | 29.37 | 0.56 | 0.00% | 1.84 | 17.32% |
Watch List Summary
A View on the "Buy Low, Sell High" Concept
One way that the New Low Observer (NLO) has managed to isolate whether a stock is at a low price is by waiting until the stock is within 20% of the new low. This approach isn't a cure for what ails the average investor. However, it does allow average market participants the opportunity to investigate quality companies for potential price increases. The new low of a stock automatically implies that value has been created especially if the company in question can survive as a going concern. This is counter to most information coming out of the Wall Street media machine. Typically, analysts on Wall Street recommend stocks that have risen far above the low before initiating coverage on a stock.
While there are 4336 individual stocks that can be bought on American stock exchanges, NLO has determined that there are basically only 383 companies that warrant your attention. The first group of companies are known as the Dividend Achievers (excel list of companies). These 283 companies are tracked by Mergent's based on their ability to increase their dividends every year for over 10 years in a row as a minimum requirement. It goes without saying that these companies pay some kind of dividend with yields that range from over 5% to less than 1%.
The second major group of companies tracked by NLO are the constituents of the Nasdaq 100. In our earlier forms as Dividend Inc. and Arti Invest, we believed that only Dividend Achievers were worth tracking since the dividend payment was verifiable regardless of "accounting" inconsistencies that are commonly found with "other" companies. The performance of this approach has been well documented and proven quite profitable.
However, the reality of the stock market dictates that we widen our perspective on companies that might afford significant opportunity with reduced risk. We, at NLO, decided that the Nasdaq 100 was the next obvious choice. After all, most mutual funds are bound to invest in these companies regardless of their unwillingness to pay dividend income. Additionally, companies in the Nasdaq 100 have solid reputations with higher prospects for growth over the long term.
One recent example of the benefit of tracking and research companies posted on NLO, as opposed to those from the Wall Street media machine, is Stericycle (SRCL). SRCL last appeared on our Nasdaq 100 watch list on October 30th. After being on our watchlist since the July 24th initiation of our website, SRCL has managed to climb from the low of $47.76 to the most recent high of $58. This is an increase of 18% from the July low and 21% from the October low and 11.54% from the breakout above our watch list range of being within 20% of the 52-week low.
NLO can be easily contrasted with the recent short-term buy recommendation placed on SRCL by Zack's Investment Research. In a tiny blurb issued today, Zack's Investment Research indicated that SRCL's stock had been in an oversold state based on the stochastics which indicated or implied that the stock was likely to go higher in the near term.
SRCL is only one of the companies that has been on the NLO Nasdaq 100 Watchlist that performed exceptionally well after getting off the list. Below are other Nasdaq 100 companies and their performance since getting within 20% of the new low:
- ILMN up 31.69% from the low
- FLIR up 76.45%
- PPDI up 31.11%
- VRSN up 45.77%
- ERTS up 27.95%
- BIIB up 28.62%
- AMGN up 27.98%
- RYAAY up 23.75%
It should be noted that the above companies are almost the entire list of companies that have appeared on the Nasdaq 100 Watch List. So far, this implies that quality Nasdaq companies could be investigated for speculative opportunities near the new low. Hopefully this approach can provide a reasonable approach to buying low with the prospect of selling higher. Follow along with us as we continue to investigate the speculative opportunities of the Nasdaq 100. -Touc
Nasdaq 100 Watch List
|
Symbol |
Name | Price | P/E | EPS | Yield | P/B |
% from Low |
|---|---|---|---|---|---|---|---|
|
Genzyme |
48.78 |
27.81 |
1.75 |
N/A |
1.68 |
3.59% |
|
|
Gilead |
42.83 |
16.56 |
2.59 |
N/A |
6.90 |
5.44% |
|
|
Apollo Grp |
58.40 |
15.57 |
3.75 |
N/A |
7.67 |
10.63% |
|
|
Cephalon |
59.04 |
16.32 |
3.62 |
N/A |
2.05 |
12.35% |
|
|
EA |
16.72 |
N/A |
-4.06 |
N/A |
2.02 |
17.42% |
|
|
Illumina |
27.88 |
38.78 |
0.72 |
N/A |
3.40 |
19.71% |
|
|
Biogen |
50.07 |
16.76 |
2.99 |
N/A |
2.18 |
19.93% |
Nasdaq 100 Watch List
The following are Nasdaq 100 members that are within 20% of the 52-week low:
- Genzyme Corp. (GENZ) at $49.74 within 5.63%
- Apollo Group (APOL) at $56.58 within 7.18%
- Cephalon, Inc. (CEPH) at $58.94 within 12.16%
- Electronic Arts (ERTS) at $16.11 within 13.13%
- Gilead Sciences (GILD) at $46.42 within 14.28%
- Ryanair Holdings (RYAAY) at $25.34 within 16.40%
- Biogen Idec (BIIB) at $48.65 within 16.53%
- Pharma. Prod. Dev. (PPDI) at $21.41 within 16.53%
Nasdaq 100 Watch List
The following are the Nasdaq 100 members that are within 20% of the 52-week low:
-
Apollo Group, Inc. (APOL) at $55.99 within 1.16%
-
Cephalon, Inc. (CEPH) at $58.26 within 10.87%
-
Genzyme Corporation (GENZ) at $52.28 within 11.02%
-
Pharma. Products Dev. (PPDI) at $20.93 within 16.47%
-
Gilead Sciences, Inc. (GILD) at $46.26 within 17.50%
It is interesting to note the percentage change that has occurred in last week's Nasdaq 100 watch list. Last week's list had the following one week percentage change:
-
APOL down 1.94%
-
CEPH up 6.74%
-
GENZ up 3.32%
-
PPDI down 2.88%
-
GILD up 8.72%
-
BIIB up 8.62%
-
SRCL up 3.69%
-
AMGN up 2%
The biotech/pharma sector is moving higher. As we've stated before, these companies are very undervalued at the present time. Do your research and carefully consider the opportunities. Touc.
Nasdaq 100 Watch List
The following are the Nasdaq 100 members that are within 20% of the 52-week low:
-
Apollo Group, Inc. (APOL) at $57.10 within 3.16%
-
Cephalon, Inc. (CEPH) at $54.58 within 3.86%
-
Genzyme Corporation (GENZ) at $50.60 within 7.45%
-
Gilead Sciences, Inc. (GILD) at $42.55 within 8.08%
-
Biogen Idec Inc (BIIB) at $42.13 within 13.22%
-
Stericycle, Inc. (SRCL) at $52.37 within 18.06%
-
Amgen Inc. (AMGN) at $53.62 within 19.26%
-
Pharmaceutical Product Developm (PPDI) at $21.55 within 19.92%
The fact that all of these companies (except for APOL) are within the drug industry does not surprise me. The continued undervaluation of these companies makes them prime targets for acquisition by investors and larger drug companies. Touc.


